Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006)

Michael Polydefkis(Université Paris-Sud), Annabel K. Wang(Université Paris-Sud), Stephen B. Heitner(Brigham and Women's Hospital), Morie A. Gertz(Medical University of South Carolina), Giuseppe Vita(University of Messina), Peter D. Gorevic(Université Paris-Sud), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Jesse Kwoh(Ionis Pharmaceuticals (United States)), Márcia Waddington‐Cruz(Université Paris-Sud), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Josep M. Campistol(Universitat de Barcelona), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Brett P. Monia(Ionis Pharmaceuticals (United States)), Fábio Barroso(Université Paris-Sud), Acary Souza Bullé Oliveira(Universidade Federal de São Paulo), Carol Whelan(The Royal Free Hospital), Thomas H. Brannagan(Columbia University), Isabel Conceição(Université Paris-Sud), Brian Drachman(Penn Presbyterian Medical Center), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Morton Scheinberg(Université Paris-Sud), Edward Gane(University of Auckland), David Adams(Mount Sinai Health System), Teresa Coelho(Universidade do Porto), Elizabeth J. Ackermann(Université Paris-Sud), P. James B. Dyck(Mayo Clinic), Merrill D. Benson(Indiana University School of Medicine), Bradley McEvoy(Université Paris-Sud)

Neurology

April 10, 2018

Cited by 0

|New England Journal of Medicine|2019|3.6k

|New England Journal of Medicine|2018|2.9k

|New England Journal of Medicine|2018|2.8k

|Leukemia|2006|2.6k

|Cell Metabolism|2006|2.1k

Related Papers